CLDN23抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Hela cells, Primary antibody: P00287(CLDN23 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P00287(CLDN23 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The claudin-23 (CLDN23) antibody is a research tool targeting CLDN23. a member of the claudin family of transmembrane proteins critical for forming tight junctions in epithelial and endothelial cells. These junctions regulate paracellular permeability and maintain cellular polarity. CLDN23. though less studied compared to other claudins, is implicated in tissue-specific barrier functions and may play roles in pathological conditions. Its expression has been observed in organs like the intestines, kidneys, and liver, with emerging links to diseases such as inflammatory bowel disease (IBD) and certain cancers. For instance, altered CLDN23 expression has been associated with colorectal cancer progression, suggesting its potential as a biomarker or therapeutic target.

CLDN23 antibodies enable the detection and localization of the protein via techniques like immunohistochemistry, Western blotting, and immunofluorescence. These antibodies aid in studying CLDN23's interaction with other tight junction components, its regulation under physiological or pathological stimuli, and its involvement in pathogen entry or immune response modulation. Recent studies also explore its role in maintaining gut barrier integrity, where dysregulation could contribute to microbial translocation and inflammation. While most applications remain preclinical, CLDN23 antibodies hold promise for elucidating tissue-specific barrier mechanisms and developing targeted therapies. Further research is needed to clarify its precise functional roles and therapeutic relevance across diseases.